Argos Therapeutics, which is developing immunotherapies for the treatment of renal cell carcinoma and HIV, raised $45 million by offering 5.625 million shares (all primary) at $8. The company had originally filed to sell 4.25 million shares at a range of $13 to $15. Argos Therapeutics plans to list on the NASDAQ under the symbol "ARGS". Piper Jaffray, Stifel and JMP Securities acted as lead managers on the deal.
